Complicity Theory: An Explanation for the ‘Coxib Problem’?

Caldwell B. , Aldington S. , Weatherall M. , Shirtcliffe P. , Beasley R. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med 2006; 99: 132–40

Curfman G. , Morrissey S. , Drazen J. Expression of Concern Reaffirmed. N Engl J Med 2006; 354: 1193

Weatherall M. , Aldington S. , Caldwell B. , Beasley R. Inconsistencies in cardiovascular data from COX-2 inhibitor trials—is it a CLASS effect? J R Soc Med 2006; 99: 275–6

Hawkey C. , Langman M. Non-steroidal anti-inflammatory drugs: overall riks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut 2003; 52: 600–8

Silverstein F.E. , Faich G. , Goldstein J.L. . Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study. JAMA 2000; 284: 1247–55

Bombardier C. , Laine L. , Reicin A. . Comparison of upper gastrointestinal toxicity with rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. N Engl J Med 2000; 343: 1520–8

McAdam B. , Catella-Lawson F. , Mardini I. , Kapoor S. , Lawson J. , Fizgerald G. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Nat Acad Sci 1999; 96: 272–7

Dieppe P. , Bartlett C. , Davey P. , Doyal L. , Ebrahim S. Balancing benefits and harms: the example of non-steroidal anti-inflammatory drugs. BMJ 2004; 329: 31–4

Dieppe P. , Ebrahim S. , Martin R. , Juni P. Lessons from the withdrawal of rofecoxib. BMJ 2004; 329: 867–8

Kline A. On complicity theory. Sci Eng Ethics 2006; 12: 257–64

[http://www.nofreelunch.org]

Watson D. , Rhodes T. , Cai B. , Guess H. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002; 162: 1105–10

Juni P. , Rutjs A.W. , Dieppe P.A. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ 2002; 324: 1287–8

Angell M. The Truth About The Drug Companies: How They Deceive Us and What To Do About It. London: Random House, 2005

Weber L. Profits Before People?: Ethical Standards and The Marketing and Prescription of Drugs. Indiana: Indiana University Press, 2006

Marteau T. , Dieppe P. , Foy R. , Kinmonth A.L. , Schneiderman N. Behavioural medicine: changing our behaviour. BMJ 2006; 332: 437–8

Moynihan R. , Cassels A. Selling Sickness: How The World's Biggest Pharmaceutical Companies Are Turning Us All Into Patients. California: Avalon Publishing Group, 2005